FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:841-842 March 15, 2001 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Slamon, D. J. PubMed Citation

Much of the fundamental cancer research of the past two decades has focused on identifying the molecular and genetic changes that cause malignant transformation. These abnormalities can be attractive targets for the development of anticancer treatments. The family of epidermal growth factor–receptor tyrosine kinases, which includes epidermal growth factor receptor (EGFR, or ErbB-1), HER2 (ErbB-2), ErbB-3, and ErbB-4, has attracted considerable interest because many epithelial tumors, including breast cancer, express excess amounts of these proteins, particularly EGFR and HER2. In this issue of the Journal, Slamon et al. present important results of a randomized trial of a monoclonal antibody against . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Yamaguchi, N., Oyama, T., Ito, E., Satoh, H., Azuma, S., Hayashi, M., Shimizu, K., Honma, R., Yanagisawa, Y., Nishikawa, A., Kawamura, M., Imai, J.-i., Ohwada, S., Tatsuta, K., Inoue, J.-i., Semba, K., Watanabe, S. (2008). NOTCH3 Signaling Pathway Plays Crucial Roles in the Proliferation of ErbB2-Negative Human Breast Cancer Cells. Cancer Res. 68: 1881-1888 [Abstract] [Full Text]  
• Barrett, C., Magee, H., O'Toole, D., Daly, S., Jeffers, M. (2007). Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?. J. Clin. Pathol. 60: 690-693 [Abstract] [Full Text]  
• Weinshilboum, R., Wang, L. (2006). Pharmacogenomics: Bench to Bedside. Focus 4: 431- [Abstract] [Full Text]  
• Biswas, D. K., Shi, Q., Baily, S., Strickland, I., Ghosh, S., Pardee, A. B., Iglehart, J. D. (2004). NF-{kappa}B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc. Natl. Acad. Sci. USA 101: 10137-10142 [Abstract] [Full Text]  
• Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., Pollak, M. (2001). Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). JNCI J Natl Cancer Inst 93: 1852-1857 [Abstract] [Full Text]  
• Behr, T. M., Behe, M., Wormann, B., Strasser, F., Betticher, D. C., Suter, T. M., Palmieri, C., Powles, T., Vigushin, D., Rudlowski, C., Rath, W., Becker, A. J., Wiestler, O. D., Buttner, R. (2001). Trastuzumab and Breast Cancer. NEJM 345: 995-998 [Full Text]  
• Roukos, D. H., Kappas, A. M. (2001). Limitations in Controlling Risk for Recurrence After Curative Surgery for Advanced Gastric Cancer Are Now Well-Explained by Molecular-Based Mechanisms. Ann. Surg. Oncol. 8: 620-621 [Full Text]